Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    cellenkos
Previous Study | Return to List | Next Study

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs (TREG108)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05423691
Recruitment Status : Not yet recruiting
First Posted : June 21, 2022
Last Update Posted : June 30, 2022
Sponsor:
Information provided by (Responsible Party):
Cellenkos, Inc.

Brief Summary:
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Condition or disease Intervention/treatment Phase
Myelofibrosis Drug: CK0804 Phase 1

Detailed Description:
  1. Safety Run-in

    The study will employ a 3+3+3 design to assess the safety and tolerability of the treatment based on treatment-limiting toxicities (TLTs) occurring up to 1 Cycle (28 days) after the first infusion.

  2. Expansion

After a total of 9 participants completed 28 days and are evaluated for tolerability in the safety run-in phase, additional participants may be included in the expansion cohort in order to have approximately 24 evaluable myelofibrosis

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a single-arm study consisting of a safety run-in (3+3+3 design) followed by an expansion cohort after completion of safety run-in data is evaluated for tolerability in the safety.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib
Estimated Study Start Date : August 3, 2022
Estimated Primary Completion Date : October 30, 2023
Estimated Study Completion Date : April 30, 2024


Arm Intervention/treatment
Experimental: Arm 1
CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.
Drug: CK0804
CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.




Primary Outcome Measures :
  1. To determine Treatment limiting toxicity (TLT) as defined below [ Time Frame: 28 days ]
    • severe (grade 3 or 4) infusion-related toxicity within 24 hours (NCI-CTCAE V5.0) of exposure that does not resolve with standard of care treatment within 72 hours.
    • regimen related death within 28 days


Secondary Outcome Measures :
  1. Assessment of overall response rate (ORR) (measured as CR or PR) and its duration, using modified International Working Group-Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) consensus report. [ Time Frame: 6 months ]
    To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

  2. Rate of anemia response as per modified IWG-MRT ELN response criteria. [ Time Frame: 6 months ]
    To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

  3. Rate of spleen response by imaging at and after 24 weeks as per IWG-MRT ELN response criteria [ Time Frame: 6 months ]
    To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

  4. Percentage of Participants who will Achieve Total Symptom Score Reduction Greater Than or Equal to (≥) 50% (TSS50) as Measured by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) [ Time Frame: 6 months ]
    To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study.
  2. Age above 18 years inclusive at the time of signing the ICF.
  3. Participants who fulfill the diagnostic criteria of myelofibrosis including primary myelofibrosis and myelofibrosis arising from polycythemia vera and essential thrombocythemia
  4. Life expectancy is greater than 6 months.
  5. Subject has been receiving ruxolitinib therapy, is unlikely to benefit from further ruxolitinib monotherapy in the opinion of the investigator; AND meeting the following criteria: receiving ruxolitinib >3 months prior to enrollment; AND stable dose for 8 weeks before starting therapy with CK0804
  6. Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of:

    • presence of grade ≥2 anemia or thrombocytopenia or neutropenia, OR
    • presence of disease-related symptoms, as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN SAF TSS) score of ≥10 points, OR
    • documented splenomegaly of at least 5 cm below the costal margin as measured by physical examination or splenomegaly as documented by ultrasound or MRI.
  7. Willingness to avoid pregnancy or fathering children based on the criteria below

    • Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last study treatment dose and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing should be communicated to the participants and their understanding confirmed.
    • Women of childbearing potential must have a negative serum pregnancy test at screening before the first dose (within 3 days of the first study treatment dose) and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through the safety follow-up visit and must not donate oocytes during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed,
    • Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible.
  8. ECOG performance status of 0 to 2

Exclusion Criteria:

  1. Any major surgery within 28 days before the first dose of study treatment.
  2. Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation.
  3. Received chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent to treat the participant's disease, with the exception of ruxolitinib, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.
  4. Participant has received splenic irradiation within the past 6 months.
  5. Significant concurrent, uncontrolled medical condition or infections, which in the opinion of the principal investigator may interfere in the study participation.
  6. Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
  7. Women who are pregnant or breastfeeding.
  8. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  9. Participants with laboratory values at screening as defined

    • Platelets < 50 × 10^9/L without the assistance of growth factors, thrombopoietic factors, or platelet transfusions
    • ANC < 0.5 × 10^9/L
    • ALT ≥ 2.5 × ULN
    • AST ≥ 2.5 × ULN
    • Direct Bilirubin > 2.0 × ULN
    • ALP ≥ 3 × ULN
    • Creatinine clearance < 50 mL/min according to Cockcroft-Gault formula.
  10. Unwillingness to be transfused with blood components including RBC and platelet transfusions.
  11. Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend the ICF or unwillingness to sign the ICF.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05423691


Contacts
Layout table for location contacts
Contact: Tara Sadeghi 713-806-4787 tara.sadeghi@cellenkosinc.com
Contact: Stacy Minor 832-962-7628 stacy.minor@cellenkosinc.com

Locations
Layout table for location information
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Contact: Alleyne Genevieve    713-792-4986    GMAlleyne@mdanderson.org   
Principal Investigator: Lucia Masarova, MD         
Sponsors and Collaborators
Cellenkos, Inc.
Publications:
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum in: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].
Kadia TM, Pemmaraju N, Yilmaz M, Li L, Lyu M, Huang M, Zeng K, Parmar S, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Verstovsek S. 2020. 'Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis', Blood, 136: 41-42.
Zeng K, Ma H, Popat U, Nieto Y, Ciurea SO, Olson AL, Lyu M, Huang M, Nishimoto M, Qazilbash MH, Ramos JD, Shpall EJ, Champlin RE, Parmar S, Andersson BS. . 2019. 'Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Tria', Blood, 134.

Layout table for additonal information
Responsible Party: Cellenkos, Inc.
ClinicalTrials.gov Identifier: NCT05423691    
Other Study ID Numbers: CK0804.101.1
First Posted: June 21, 2022    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cellenkos, Inc.:
myelofibrosis
ruxolitinib
CK0804
T regulatory cells
cord blood unit
allogeneic
Treg Cells
Bone Marrow Diseases
Hematologic Diseases
Bone Marrow Neoplasms
Myeloproliferative Disorders
Thrombocytosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Myelofibrosis
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases